ArticleIrish journal of medical science2026
Extracellular vesicle-derived miR-141, miR-10b, miR-550a and miR-16 define a circulating signature in prostate cancer.
Article in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer (PCa) diagnosis relies heavily on PSA screening, which suffers from low specificity, leading to unnecessary biopsies and overdiagnosis. Distinguishing PCa from benign prostatic hyperplasia (BPH) remains a significant clinical challenge. Extracellular vesicles (EVs) protect molecular cargo, such as microRNAs (miRNAs), from degradation and reflect the physiological state of their parental cells. Given their stability and accessibility in biological fluids, EV-associated miRNAs represent ideal liquid biopsy candidates to overcome the limitations of current diagnostic markers and improve risk stratification.
aimsThis study investigated the potential of a specific plasma EV-derived miRNA panel (miR-16, miR-141, miR-10b, miR-373, miR-409, miR-34a, miR-205, miR-145, and miR-550a) to differentiate between healthy controls, BPH, localized PCa (LPCa), and metastatic PCa (MPCa).
methodsPlasma EVs were isolated using a precipitation-based method, followed by total RNA extraction. EV-derived miRNA expression profiles were quantified via qRT-PCR. Statistical analyses were performed to compare expression levels across clinical groups and to assess their diagnostic potential.
resultsSignificant differential expression was observed for EV-derived miR-141, miR-10b, and miR-550a. miR-141 was significantly downregulated in BPH and LPCa compared to healthy controls (p < 0.05). Notably, EV-derived miR-10b and miR-550a levels were significantly lower in the MPCa group compared to BPH. When comparing all PCa cases (LPCa+MPCa) against non-cancerous groups (BPH+Control), EV-derived miR-10b and miR-550a were significantly downregulated, while miR-16 showed upregulation in the cancer cohort.
conclusionOur findings demonstrate that specific plasma EV-derived miRNA signatures can distinguish prostate pathologies and disease stages. These results suggest that EV-derived miR-10b, miR-141, miR-16 and miR-550a hold promise as non-invasive biomarkers for differentiating PCa from BPH, potentially reducing overdiagnosis and informing clinical management.
Indexed as
Identifiers
42277406What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.